125050-17-1

Basic information

• Product Name: tert-butyl ester of α-N-carbobenzoxy-δ-bromonorvaline
• Synonyms: tert-butyl ester of α-N-carbobenzoxy-δ-bromonorvaline
• CAS NO: 125050-17-1
• Molecular Weight: 386.286
• Mol File: 125050-17-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: tert-butyl ester of α-N-carbobenzoxy-δ-bromonorvaline(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl ester of α-N-carbobenzoxy-δ-bromonorvaline(125050-17-1)
• EPA Substance Registry System: tert-butyl ester of α-N-carbobenzoxy-δ-bromonorvaline(125050-17-1)

Safety Data

• Hazardous Substances Data: 125050-17-1(Hazardous Substances Data)

Upstream product

• 3077-51-8 γ-methyl L-glutamate hydrochloride 
• 1499-55-4 L-glutamic acid 5-methyl ester 
• 56-86-0 L-glutamic acid 
• 5891-45-2 N-benzoyloxycarbonyl L-glutamic acid α-t-butylester 
• 81470-51-1 tert-butyl N-benzyloxycarbonyl-L-pyroglutamate 
• 35418-16-7 L-t-butyl pyroglutamate 
• 124620-51-5 2-Benzyloxycarbonylamino-5-hydroxy-pentanoic acid tert-butyl ester 
• 5891-45-2 (S)-2-(benzyloxycarbonylamino)pentanedioic acid tert-butyl ester 
• 124620-51-5 (S)-tert-butyl 2-(((benzyloxy)carbonyl)amino)-5-hydroxypentanoate 
• 501-53-1 benzyl chloroformate 
• 57732-63-5 1-tert-butyl 5-methyl (2S)-2-{[(benzyloxy)carbonyl]amino}pentanedioate 
• 4652-65-7 (S)-2-Benzyloxycarbonylamino-pentanedioic acid 5-methyl ester 

Downstream Products

• 125050-19-3 N-(benzyloxy)amide of α-N-carbobenzoxy-δ-bromo-D-norvaline 
• 1023328-08-6 tert-butyl 5-(4-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-piperidin-1-yl)-N-(benzyloxycarbonyl)-L-norvalinate 
• 1023328-06-4 tert-butyl 5-(4-(6-amino-5-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-3-yl)-1H-pyrazol-1-yl)-N-(benzyloxycarbonyl)-L-norvalinate 
• 16881-39-3 (S)-2-tert-butyl-1-benzylpyrrolidine-1,2-dicarboxylate 

Relevant articles and documents

SERINE REPLACEMENT POLYMYXIN ANALOGUES USEFUL AS ANTIBIOTIC POTENTIATORS

The disclosure provides compounds of the formula I or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables R1 and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering a therapeutically effective amount of the antibacterial agent and a compound of formula I to a patient infected with the bacteria, simultaneously or sequentially.

AMINOHETEROARYL COMPOUNDS AS FOR THE TREATMENT OF DISEASES MEDIATED BY C-MET KINASE ACTIVITY

Compounds of formula (I), are inhibitors of c-Met kinase activity, useful inter alia in the treatment of hyperproliferative diseases: wherein X is -N= or -CH=; ring A is optionally substituted mono- or bi-cyclic aryl or heteroaryl having from 5 to 12 ring

ACE-INHIBITORS HAVING ANTIOXIDANT AND NO-DONOR ACTIVITY

Multifonctional ACE inhibitor compounds are provided, that combine ACE-inhibiting activity with capability to scavenge superoxide and other reactive oxygen species, and that may further function as nitric oxide donors. The compounds are useful for preventing or treating various disorders, including cardiovascular, and diabetes associated disorders.